Matthew Jones

Assistant Professor

Massachusetts Institute of Technology
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Charting the spatiotemporal dynamics of cell fate determination in development and disease is a long-standing objective in biology. Here, we present the design, development, and extensive validation of PEtracer, a prime editing (PE)–based, evolving lineage tracing technology compatible with both single-cell sequencing and multimodal imaging methodologies, created to jointly profile cell state and lineage in dissociated cells or while preserving cellular context in tissues with high spatial resolution. Using PEtracer coupled with MERFISH spatial transcriptomic profiling in a syngeneic mouse model of tumor metastasis, we reconstructed the growth of individually seeded tumors in vivo and uncovered distinct modules of cell-intrinsic and -extrinsic factors that coordinate tumor growth. More generally, PEtracer enables systematic characterization of cell state and lineage relationships in intact tissues over biologically relevant temporal and spatial scales.

Year:

2025

Oncogene amplification on extrachromosomal DNA (ecDNA) is a pervasive driver event in cancer, yet our understanding of how ecDNA forms is limited. In this study, we couple a CRISPR-based method for ecDNA induction with extensive characterization of newly formed ecDNAs to examine their biogenesis. We find that DNA circularization is efficient, irrespective of 3D genome context, with the formation of 800 kb, 1 Mb, and 1.8 Mb ecDNAs reaching or exceeding 15%. We show nonhomologous end joining and microhomology-mediated end joining both contribute to ecDNA formation, whereas inhibition of DNA-PK catalytic subunit and ATM have opposing impacts on ecDNA formation. ecDNA and the corresponding chromosomal excision scar can form at significantly different rates and respond differently to DNA-PK catalytic subunit and ATM inhibition. Taken together, our results support a model of ecDNA formation in which double-strand break ends dissociate from their legitimate ligation partners prior to joining of illegitimate ends to form the ecDNA and excision scar. Significance: Our study harnesses a CRISPR-based method to examine ecDNA biogenesis, uncovering efficient circularization between double-strand breaks. ecDNAs and their corresponding chromosomal scars can form via nonhomologous end joining or microhomology-mediated end joining, but the ecDNA and scar formation processes are distinct. Based on our findings, we establish a mechanistic model of excisional ecDNA formation.

Year:

2025

Foundation models have transformed natural language processing and computer vision, yet their potential in single-cell biology—particularly for complex diseases such as cancer— remains underexplored. We present Tahoe-x1 (Tx1), a family of perturbation-trained single-cell foundation models with up to 3 billion parameters. Tx1 is pretrained on large-scale single-cell transcriptomic datasets, including the Tahoe-100M perturbation compendium, and fine-tuned for cancer-relevant tasks. Through architectural optimizations, data loader refinements, and efficient training strategies, Tx1 achieves 3–30× higher compute efficiency than prior implementations of cell-state models. Tx1 jointly learns representations of genes, cells, and compounds using a masked-expression generative objective that incorporates a drug token, enabling flexible adaptation to diverse downstream applications. We evaluate Tx1 across four key disease-relevant benchmarks: (1) prediction of overall and context-specific gene essentiality, (2) identification of genes contributing to the hallmarks of cancer, (3) cell-type classification, and (4) prediction of perturbation responses in held-out cellular contexts. Tx1 achieves state-of-the-art performance across all tasks. We release pretrained checkpoints, training code, and evaluation workflows to accelerate the development of perturbation-trained single-cell foundation models for applications in precision oncology and beyond.

Year:

2025

Workflow of the study analysis. A, A total of 94 IDH wt GBMs were analyzed (35 from the PCAWG cohort and 59 from the GB-UK cohort). B, The core region of all patient tumors was analyzed using WGS, and GB-UK patient tumors were further subjected to multiregion DNA FISH and nascent RNAscope analysis to characterize spatial patterns of oncogenic ecDNAs. C, The ecDNA genetic landscape and fine structure were analyzed using WGS information, and mathematical modeling of single-cell copy number was employed to reconstruct evolutionary histories in GB-UK patient tumors. ( B, created using BioRender assets. https://BioRender.com/kgae4q5 ; https://BioRender.com/7f2pume )

Year:

2025

Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA. We observe oncogene-specific patterns of ecDNA spatial heterogeneity, emerging from random ecDNA segregation and differing fitness advantages. Unlike PDGFRA -ecDNAs, EGFR -ecDNAs often accumulate prior to clonal expansions, conferring strong fitness advantages and reaching high abundances. In corroboration, we observe pretumor ecDNA accumulation in vivo in genetically engineered mouse neural stem cells. Variant and wild-type EGFR -ecDNAs often coexist in GBM. Those variant EGFR -ecDNAs, most commonly EGFRvIII -ecDNA, always derive from preexisting wild-type EGFR -ecDNAs, occur early, and reach high abundance. Our results suggest that the ecDNA oncogenic makeup determines unique evolutionary trajectories. New concepts such as ecDNA clonality and heteroplasmy require a refined evolutionary interpretation of genomic data in a large subset of GBMs. Significance: We study spatial patterns of ecDNA-amplified oncogenes and their evolutionary properties in human GBM, revealing an ecDNA landscape and ecDNA oncogene–specific evolutionary histories. ecDNA accumulation can precede clonal expansion, facilitating the emergence of EGFR oncogenic variants, reframing our interpretation of genomic data in a large subset of GBMs. See related commentary by Korsah et al., p. 1979

Year:

2025

Simulating multi-ecDNA dynamics in vivo. A, DNA FISH and nascent RNAscope images from the tumor of patient A5, showing the coexistence of both EGFR -ecDNA and PDGFRA -ecDNA. B, Circular structures of three distinct oncogenic ecDNAs detected in the tumor of patient A5. C, GBMs in the GB-UK and PCAWG cohorts containing more than one oncogenic species and their respective copy numbers. D, In a multiple-ecDNA application of SPECIES, the clone-initiating cell begins with k 1 and k 2 copies of ecDNA 1 and ecDNA 2, respectively. E, Representation of the impacts of ecDNA cosegregation and coselection on the number of inherited ecDNA copies during cell division. Cosegregation drives correlated inheritance of both ecDNA types, whereas coselection favors tumor cells carrying at least one copy of each type. F, Application of SPECIES to simulate two separate ecDNA species. Simulated tumors were initialized with a single cell, carrying k 1 and k 2 copies of each ecDNA species. Representative model images show examples of low and high cosegregation and coselection. G and H, Parameter inference summary for the tumor of patient A5, for which we measured both the EGFR -ecDNA and PDGFRA -ecDNA copy-number distributions using DNA FISH, using multiple-ecDNA SPECIES. Parameters s p and s m represent selection coefficients for tumor cells with 1 (pure) or 2 (mixed) ecDNA species, respectively. I, Comparison of inferred k and k 1 values for all patient tumors confirmed by WGS to harbor two or more ecDNA species. J, The presence of ecDNA amplifications may be used to aid stratification, given that oncogenes on ecDNA have an inherent resistance mechanism through the ability of ecDNA to dynamically adjust copy number in response to targeted agents. Earlier monitoring and intervention are recommended for those patient tumors with ecDNA that will receive targeted therapies.

Year:

2025

Selection dynamics of EGFR SVs on ecDNA. A, A subclonal EGFRvIII variant on ecDNA in the tumor of patient A23. B, Variant heteroplasmy in the core region of all samples across the GB-UK and PCAWG cohorts, which contained EGFR variant–bearing ecDNA. C, Effects of (i) pre- and (ii) postclonal expansion mutation of EGFR -ecDNA on its resulting spatial pattern in the expanded tumor. D, SPECIES was applied to simulate the emergence of an advantageous EGFRvIII mutation on ecDNA, either prior to or after the onset of clonal expansion of the tumor. The example shown is for a pre-expansion mutation, with parameters ( k w t = 20 , k v a r = 1 , V v a r = 0 ). The SD of ecDNA heteroplasmy is shown by the shaded region in the lower plot. E, Model predictions for resulting variant heteroplasmy in a tumor for a range of wild type- and variant-bearing ecDNA copy numbers in the clone-initiating tumor cell (for pre-expansion EGFR mutation) and mutation times (for post-expansion EGFR mutation). The red-shaded region denotes parameter combinations inconsistent with observed patient core heteroplasmy values. Mean ± variance is derived from 1,000 simulated tumors. F, SPECIES model predictions for the probability of observing EGFRvIII ecDNA across tumor core and margin, for a pair of core and random margin regions. Mean values are derived from 1,000 simulated tumors. G, (Top) IHC slide for the tumor of patient A20, showing the presence of EGFRvIII in the tumor core and infiltrating margin (blue = hematoxylin; brown = EGFRvIII ). (Bottom) Summary of EGFRvIII in core and margins of GB-UK cohort samples, determined by IHC. H, Variant allele frequencies of point mutations within EGFR in PCAWG samples harboring EGFR -ecDNA. Red lines represent the frequency expected for a mutation carried by all ecDNAs within a sample. I, Distributions of EGFR wt-ecDNA abundance in the cell that acquires the first mutation, for a range of ecDNA mutation rates. Patient tumor values are derived from their respective inferred k values, assuming that the arrival of a mutation on ecDNA initiates clonal expansion, implying that the number of EGFR wt-ecDNA in the mutating cell is thus equal to k − 1 (with the remaining one ecDNA carrying the mutated allele). J, Timeline of EGFR -ecDNA tumorigenesis. ( i ) Initial EGFR wt-ecDNA is generated and accumulates in precancerous cells, conferring a moderately positive selective advantage. In time, the EGFRvIII mutation occurs on one of the accumulated EGFR wt-ecDNAs, conferring a strong positive advantage. ( ii ) Reconstructed ecDNA structures from the tumor of GB-UK patient A5 confirm that EGFR wt and EGFRvIII ecDNAs share common breakpoints, indicating that EGFRvIII arose from the mutation of an existing EGFR wt-ecDNA. (iii) EGFRvIII -ecDNA further promotes clonal expansion, driving tumor growth.

Year:

2025

SPECIES spatial modeling of ecDNA evolution. A and B, DNA FISH staining of two representative GBM samples from the GB-UK cohort, revealing ( A ) EGFR - and ( B ) PDGFRA -ecDNA. EGFR -ecDNA seem to congregate into “hubs” (white arrows). Single-cell ecDNA copy-number distributions are derived from DNA FISH images using unbiased image analysis. C, (i) SPECIES is initiated with a single tumor cell containing k copies of ecDNA. (ii) Model of ecDNA selection. Cells carrying one or more copies of ecDNA divide at a rate s faster than cells lacking ecDNA. (iii) Cells push neighbors within a radius q on the lattice to make space required for cell division. D, Spatial computational model of ecDNA-driven tumors. ABC was used to infer optimal model parameters for the initial number of ecDNA, k ; ecDNA-conferred selection, s ; and cell pushing strength, q , for a given set of patient tumor measurements. E and F, Example output of the ABC model fitting algorithm using ( E ) 2 and ( F ) 3 spatial regions. (Left to right) Inferred k , s , and q and model best-fit distributions for each tumor region. The sum of the Wasserstein distance between patient and simulated distributions for each tumor region, representing closeness of fit, is denoted by σ. G, Comparison of inferred k , s , and q when analyzing 2 (core and margin) vs. 3 (core, margin, and leading edge) spatial regions. H, Summary of inferred model parameters for all sampled human GBM tumors. The highlighted color represents ecDNA-amplified oncogenes ( EGFR , PDGFRA , or CDK4 ) in each tumor. I, Inferred model parameters for all patient tumors (excluding the tumor of patient A5, which contained separate EGFR- and PDGFRA -ecDNA species), stratified by ecDNA-amplified oncogene ( EGFR or PDGFRA ). ( D, created using BioRender assets. https://BioRender.com/7f2pume )

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (23)

Xiaowei Zhuang

Harvard University

UNITED STATES
View details

Can Ergen

Group Leader

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY
View details

Vineet Bafna

Professor

University of California, San Diego

UNITED STATES
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Andrea Ventura

Member

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Benjamin Werner

Reader in Somatic Evolution

Barts Cancer Institute

UNITED KINGDOM
View details

Luke Koblan

Whitehead Institute for Biomedical Research

UNITED STATES
View details

Jonathan Weissman

Whitehead Institute for Biomedical Research

UNITED STATES
View details

Mariam Jamal-Hanjani

Group Leader and Thoracic Oncologist

University College London

UNITED KINGDOM
View details

Nir Yosef

Weizmann Institute of Science

ISRAEL
View details

Thomas Santarius

University of Cambridge

UNITED KINGDOM
View details

Howard Y. Chang

Stanford University School of Medicine

UNITED STATES
View details

Edridge D'Souza

Columbia University

UNITED STATES
View details

Clare Weeden

The Francis Crick Institute

UNITED KINGDOM
View details

Delphine Boche

Professor of Neuroimmunopathology

University of Southampton

UNITED KINGDOM
View details

Weini Huang

Senior Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Brooke E. Howitt

Stanford University School of Medicine

UNITED STATES
View details

Calvin Kuo

Professor

Stanford University

UNITED STATES
View details

Hani Goodarzi

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Paul S. Mischel

Stanford University School of Medicine

UNITED STATES
View details

Natasha Weiser

Assistant Professor

Yale University

UNITED STATES
View details

William Allen

Assistant Professor

Stanford University

UNITED STATES
View details

Mary Green

Deputy Head of Experimental Histopathology

The Francis Crick Institute

UNITED KINGDOM
View details